Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations —After FDA rejection, Gilead nears full EU nod for hep D drug — Judge orders J&J, talc opponents to engage in settlement talks -- See more on our front page news http://bit.ly/w28kSd #earnings #biogen #novartis #sanofi #gileadsciences #hepatitisd #legal #bankruptcy #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#earnings #biogen #novartis #Sanofi #gileadsciences #hepatitisd #legal #bankruptcy #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Referenced link: https://medicalxpress.com/news/2023-03-real-world-effectiveness-bulevirtide-chronic-hepatitis.html
Discuss on https://discu.eu/q/https://medicalxpress.com/news/2023-03-real-world-effectiveness-bulevirtide-chronic-hepatitis.html
Originally posted by Phys.org / @physorg_com: http://nitter.platypush.tech/medical_xpress/status/1637883220350869505#m
RT by @physorg_com: Real-world studies confirm effectiveness of bulevirtide to treat chronic ##hepatitisD https://linkinghub.elsevier.com/retrieve/pii/S0168827822029804 https://medicalxpress.com/news/2023-03-real-world-effectiveness-bulevirtide-chronic-hepatitis.html